Find Out If You Are a Match for the X-TOLE2 Trial
Through an innovative collaboration with Neuroventis and Embleema, we’ve made it easy for patients to pre-screen and discover if they may qualify for this groundbreaking clinical trial.
If you are a match, you have the opportunity to contribute to significant advancements in medical knowledge and help improve treatments for patients like yourself. Your participation can make a substantial impact on epilepsy healthcare.
Get Matched by Registering on Embleema
Create a Profile: Provide basic health information to get started.
Find a Match: Answer the 'My Epilepsy' questionnaire. Our platform identifies whether you are a match for the clinical trial.
Connect & Enroll: A trial coordinator will get in touch to help you learn more and begin the enrollment process.
Determine Your Eligibility In a Few Steps
After sign-up, answer questions about your epilepsy to be matched. You may qualify for the X-TOLE2 study if you:
Have been diagnosed with focal epilepsy (seizures occurring on only one side of the brain) for 2+ years
Are on a stable dose of 1–3 anti-seizure medications
Have tried at least 2 anti-seizure medications but are still experiencing seizures
Why Participate?
If eligible and enrolled, participants in the study may receive:
Study medication at no cost
Epilepsy-related study medical care
Compensation for study visits
Travel expense reimbursements
After the initial screening, your study doctor will explain these benefits in detail and answer any questions about the trial.
What is the Battling Epilepsy Together (BET) Program?
Advancing Epilepsy Research Through Decentralized Data
The Battling Epilepsy Together (BET) program, powered by Embleema, is revolutionizing epilepsy care with a patient-first digital ecosystem. Launched in 2022, this decentralized registry collects real-world data from diverse epilepsy patients, including those in remote areas, providing insights into disease management, medications, and patient responses.
Patients and caregivers maintain full control of their data while contributing to research and accessing personalized tools like S-Check and seizure diaries. With consent, data is shared across stakeholders, breaking down silos and advancing personalized epilepsy treatment.
1
Tap the button below to create your account with Embleema
2
Enter your information and provide some basic details to set up your login
3
Verify your account by clicking the link sent to your email
4
Download and dive into the Embleema app, log in, and start your journey with BET
About the study team
Embleema, a New York-based healthcare technology company, has partnered with the Epilepsy Foundation to launch BET, a platform that consolidates patient health data, enables secure sharing with caregivers and researchers, and offers personalized insights for improved condition management. Embleema’s platform, trusted by the FDA, NIH, top U.S. health networks, and leading organizations, continues its commitment to empowering the epilepsy community.
Neuroventis is a digital health company specializing in neurological care. Their platform enhances patient engagement and remote monitoring, empowering individuals with neurological disorders to actively participate in their treatment. By facilitating seamless communication between patients and healthcare professionals, Neuroventis aims to improve treatment outcomes and advance neurology care.